Caroline Seymour
Articles
Sapanisertib: Poor Activity, More AEs in mRCC
February 13, 2021
Article
Sapanisertib failed to show significant activity and a favorable toxicity profile in patients with refractory metastatic renal cell carcinoma (mRCC) regardless of mTOR or PTEN status.
New MPN Treatments Improve Survival and Symptom Burden
February 03, 2021
Article
Combinations of JAK inhibitors and novel agents, such as epigenetic regulators, could help prolong survival in patients with myeloproliferative neoplasms (MPNs), providing patients with more than a reduction in spleen size and symptomatic relief, explained Shella Saint Fleur-Lominy, MD, PhD, who added that for patients who have already progressed on ruxolitinib (Jakafi), fedratinib (Inrebic), momelotinib, and pacritinib could be potential second-line options.
Immunotherapy May Highlight Neoadjuvant Treatment's Use in Lung Cancer
January 25, 2021
Article
The radiographic and pathologic responses that have been seen with checkpoint inhibitors in lung cancer bodes well for the use of neoadjuvant therapy. However, the relationship between response and long-term outcomes, specifically with regard to overall survival, will have to be teased out before they become standard practice, explained David Spigel, MD.
Immunotherapy Is Promising, Yet Understudied in Myeloid Malignancies
January 18, 2021
Article
Survival for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains poor, and although immunotherapy has been positioned as a holy grail, it would be preemptive to predict its future based on the number of small studies that have been performed to date, according to Amer Zeidan, MD, MHS.
Genetic Precursors to Pediatric Rhabdomyosarcoma Identified
January 07, 2021
Article
“But our study is pointing to new genes to consider. For example, we found that the BRCA2 gene, typically associated with adult breast and ovarian cancer, may also somehow influence the susceptibility of pediatric RMS.”
Lung Cancer Advancements Continue, Despite COVID-19
December 03, 2020
Article
The coronavirus disease 2019 (COVID-19) pandemic has become another potential complication for patients with lung cancer, said Mark G. Kris, MD, who added that although the pandemic has disrupted patient care, it has yet to stunt scientific collaboration.
Cemiplimab Is Promising for Metastatic Basal Cell Carcinoma Treatment
November 18, 2020
Article
Cemiplimab (Libtayo) demonstrated clinically meaningful antitumor activity, including durable responses, and acceptable safety in patients with metastatic basal cell carcinoma (mBCC) after progression on or intolerance to hedgehog inhibitors.
Immunotherapy for Small Cell Lung Cancer: Expert Provides Updates
November 09, 2020
Article
Chemoimmunotherapy regimens are showing promise in the treatment of SCLC.
Pediatric Osteosarcoma and Pathogenic TP53 Variants
October 19, 2020
Article
TP53 was found to be the only gene with a germline de novo pathogenic or likely pathogenic variant in pediatric patients with osteosarcoma, according to findings from the Children’s Oncology Group that were published in JCO Precision Oncology.